VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 510 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2014. The put-call ratio across all filers is 1.37 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $15,828,000 | +66.9% | 761,700 | +15.1% | 0.10% | +29.6% |
| Q3 2017 | $9,482,000 | -27.9% | 661,700 | -12.9% | 0.08% | -33.1% |
| Q2 2017 | $13,148,000 | +33.9% | 760,000 | -14.6% | 0.12% | +0.8% |
| Q1 2017 | $9,816,000 | -74.6% | 889,900 | -66.6% | 0.12% | -75.7% |
| Q4 2016 | $38,661,000 | -45.7% | 2,662,600 | -8.2% | 0.49% | -25.3% |
| Q3 2016 | $71,244,000 | -9.3% | 2,902,000 | -25.6% | 0.66% | -37.0% |
| Q2 2016 | $78,586,000 | -32.0% | 3,902,000 | -11.1% | 1.05% | +23.8% |
| Q1 2016 | $115,496,000 | +198.2% | 4,391,500 | +1052.6% | 0.85% | +217.6% |
| Q4 2015 | $38,729,000 | +578.5% | 381,000 | +1090.6% | 0.27% | +434.0% |
| Q3 2015 | $5,708,000 | -97.2% | 32,000 | -97.9% | 0.05% | -97.5% |
| Q3 2014 | $204,610,000 | +106.4% | 1,559,527 | +98.5% | 1.97% | +87.1% |
| Q2 2014 | $99,111,000 | – | 785,847 | – | 1.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACCIPITER CAPITAL MANAGEMENT, LLC | 2,373,210 | $47,796,000 | 39.06% |
| Claren Road Asset Management, LLC | 77,527 | $1,561,000 | 18.46% |
| Okumus Fund Management Ltd. | 4,242,012 | $85,434,000 | 14.79% |
| Chou Associates Management | 1,446,843 | $29,139,000 | 11.12% |
| FARLEY CAPITAL L.P. | 307,458 | $6,192,000 | 9.65% |
| HAP Trading, LLC | 3,129,700 | $112,397,000 | 6.58% |
| Pershing Square Capital Management | 21,591,122 | $434,845,000 | 5.79% |
| NORTH TIDE CAPITAL, LLC | 2,500,000 | $50,350,000 | 5.61% |
| Convector Capital Management, LP | 192,000 | $3,867,000 | 5.34% |
| Nebula Capital Management, LP | 31,770 | $640,000 | 5.07% |